Amy Pickar Abernethy, MD

Adjunct Professor in the Department of Medicine
Professor in the School of Nursing
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3436, Durham, NC 27710
Phone (919) 668-0647
Email address amy.abernethy@duke.edu

Amy P. Abernethy, MD PhD
Director, Center for Learning Health Care
Director, Duke Cancer Care Research Program
Professor of Medicine, Department of Medicine, Division of Medical Oncology, Duke University School of Medicine
Associate Professor of Nursing, Duke University School of Nursing

Dr. Abernethy, a hematologist/oncologist and palliative care physician, is Professor of Medicine in the Duke University School of Medicine, Director of the Duke Center for Learning Health Care (CLHC) in the Duke Clinical Research Institute, and Director of the Duke Cancer Care Research Program (DCCRP) in the Duke Cancer Institute. With over 375 publications, she is an internationally recognized expert in health services research, comparative effectiveness research, patient reported outcomes (PROs), clinical informatics and patient-centered care.

Dr. Abernethy is an appointee to the Institute of Medicine’s National Cancer Policy Forum, Immediate Past President of the American Academy of Hospice & Palliative Medicine (AAHPM), Secretary of the Board of Directors for the Personalized Medicine Coalition, Co-Chair of the National Institutes of Health (NIH)-funded Palliative Care Research Cooperative Group, Co-Chair of the PRO Core for the NIH Collaboratory Program, and Chair of the PRO Task Force for the Patient Centered Outcomes Research Institute National Clinical Research Network.  She Co-Leads the Learning Health System Training Program at Duke.  She serves on the Board of Directors for athenahealth.  Dr. Abernethy participates integrally in current high-level national and international discussions about reforming the evidence development system, presenting a model for a rapid learning health care that coordinates clinical and research functions to better serve patients’ needs in an evidence-driven, cost-effective, and patient-centered manner.

Clinically, Dr. Abernethy was previously responsible for the care of patients with melanoma, in conjunction with the surgeons and radiation oncologists of the Duke Melanoma Clinic. She is Principal Investigator on major international studies for metastatic melanoma, and has published in areas pertinent to the epidemiology of melanoma, longitudinal care patterns, and improving the melanoma patient experience. Dr. Abernethy also previously attended on Duke's palliative care service, with special focus on improving the quality of life for people affected by advanced cancer including their families. Dr. Abernethy completed medical training, residency, and a fellowship in hematology and oncology at Duke University.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1999 - 2001
  • Chief Medical Resident, Medicine, Duke University, 1998 - 1999
  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 1998
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Duke University, 1994

Publications

Bull, J, Kamal, AH, Harker, M, Taylor, DH, Bonsignore, L, Morris, J, Massie, L, Singh Bhullar, P, Howell, M, Hendrix, M, Bennett, D, and Abernethy, A. "Standardization and Scaling of a Community-Based Palliative Care Model." Journal of palliative medicine 20, no. 11 (November 2017): 1237-1243.

PMID
28813635
Full Text

Tjia, J, Kutner, JS, Ritchie, CS, Blatchford, PJ, Bennett Kendrick, RE, Prince-Paul, M, Somers, TJ, McPherson, ML, Sloan, JA, Abernethy, AP, and Furuno, JP. "Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness." Journal of palliative medicine 20, no. 10 (October 2017): 1098-1103.

PMID
28520522
Full Text

Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic oncology 147, no. 1 (October 2017): 98-103.

PMID
28743369
Full Text

Granger, BB, Locke, SC, Bowers, M, Sawyer, T, Shang, H, Abernethy, AP, Bloomfield, RA, and Gilliss, CL. "The Digital Drag and Drop Pillbox: Design and Feasibility of a Skill-based Education Model to Improve Medication Management." The Journal of cardiovascular nursing 32, no. 5 (September 2017): E14-E20.

PMID
28282304
Full Text

Abernethy, AP, Gippetti, J, Parulkar, R, and Revol, C. "Use of Electronic Health Record Data for Quality Reporting." August 2017.

Full Text

Kelleher, SA, Dorfman, CS, Plumb Vilardaga, JC, Majestic, C, Winger, J, Gandhi, V, Nunez, C, Van Denburg, A, Shelby, RA, Reed, SD, Murphy, S, Davidian, M, Laber, EB, Kimmick, GG, Westbrook, KW, Abernethy, AP, and Somers, TJ. "Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART." Contemporary clinical trials 57 (June 2017): 51-57.

PMID
28408335
Full Text

Currow, D, Temel, JS, Abernethy, A, Milanowski, J, Friend, J, and Fearon, KC. "ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia." Annals of Oncology (May 4, 2017).

Full Text

DiGiacomo, M, Hatano, Y, Phillips, J, Lewis, J, Abernethy, AP, and Currow, DC. "Caregiver characteristics and bereavement needs: Findings from a population study." Palliative medicine 31, no. 5 (May 2017): 465-474.

PMID
27501720
Full Text

Bhavsar, NA, Harrison, MR, Hirsch, BR, Creel, P, Wolf, SP, Samsa, GP, Abernethy, AP, Simantov, R, Borham, A, and George, DJ. "Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer." Cancer investigation 35, no. 5 (May 2017): 333-344.

PMID
28368708
Full Text

Abernethy, AP, Arunachalam, A, Burke, T, McKay, C, Cao, X, Sorg, R, and Carbone, DP. "Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting." PloS one 12, no. 6 (January 2017): e0178420-.

PMID
28644837
Full Text

Pages